Publication date: May 30, 2025
Primary: To evaluate the level of sedation, use, daily doses, and duration of analgosedative drugs in COVID-19 patients on mechanical ventilation (MV) using a standardized protocol, comparing survivors and non-survivors. Secondary: To identify independent predictors of hospital mortality. Retrospective cohort study. Medical-surgical ICU. Adults with SARS-CoV-2 infection requiring invasive MV and continuous infusion of analgosedation and/or neuromuscular blocking agents (NMBAs) for at least 48 h. None. Level of sedation, use, daily doses, and duration of analgosedative drugs; hospital mortality and associated factors. Among 198 patients (nurse-to-patient ratio 1:2. 4; 65% staff turnover), median global RASS was -4. 5. Kaplan-Meier analysis showed lower survival with deeper sedation. Fentanyl (99%) and midazolam (97%) were the most used, followed by NMBAs (81%), propofol and dexmedetomidine (48%). Non-benzodiazepine sedatives were precribed more in survivors (88%) than non-survivors (53%) (p
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| pathway | REACTOME | SARS-CoV-2 Infection |
| drug | DRUGBANK | Etoperidone |
| drug | DRUGBANK | Fentanyl |
| drug | DRUGBANK | Midazolam |
| drug | DRUGBANK | Propofol |
| drug | DRUGBANK | Dexmedetomidine |
| drug | DRUGBANK | Benzodiazepine |